Steven Feldman to Endpoint Determination
This is a "connection" page, showing publications Steven Feldman has written about Endpoint Determination.
Connection Strength
0.051
-
Draelos ZD, Feldman SR, Butners V, Alió Saenz AB. Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study. J Drugs Dermatol. 2013 Jan; 12(1):e1-6.
Score: 0.027
-
Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat. 2011 Jun; 22(3):138-43.
Score: 0.024